End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
94.78 CNY | -4.94% | -10.03% | -24.72% |
Apr. 22 | Anhui Huaheng Biotechnology's Q1 Profit Jumps 7% | MT |
Apr. 22 | Anhui Huaheng Biotechnology's 2023 Profit Jumps 40% | MT |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
Strengths
- According to sales estimates from analysts polled by Standard & Poor's, the company is among the best with regard to growth.
- The company's profit outlook over the next few years is a strong asset.
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- The divergence of price targets given by the various analysts who make up the consensus is relatively low, suggesting a consensus method of evaluating the company and its prospects.
- Historically, the company has been releasing figures that are above expectations.
Weaknesses
- The firm trades with high earnings multiples: 23.59 times its 2024 earnings per share.
- Based on current prices, the company has particularly high valuation levels.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
Ratings chart - Surperformance
Sector: Food Processing
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-24.72% | 2.06B | - | ||
-5.67% | 27.45B | B- | ||
+18.78% | 24.56B | B | ||
+5.34% | 11.01B | B- | ||
+11.49% | 5.11B | C- | ||
+14.97% | 4.33B | B+ | ||
-13.08% | 3.62B | C | ||
-5.98% | 2.8B | C+ | ||
+25.30% | 2.75B | C+ | ||
-5.32% | 2.17B | C- |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- 688639 Stock
- Ratings Anhui Huaheng Biotechnology Co., Ltd.